Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 83

1.

A surveillance tool to support quality assurance and research in personalized medicine.

Khan NA, Peterson JF.

AMIA Annu Symp Proc. 2011;2011:701-8. Epub 2011 Oct 22.

PMID:
22195126
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project.

Pulley JM, Denny JC, Peterson JF, Bernard GR, Vnencak-Jones CL, Ramirez AH, Delaney JT, Bowton E, Brothers K, Johnson K, Crawford DC, Schildcrout J, Masys DR, Dilks HH, Wilke RA, Clayton EW, Shultz E, Laposata M, McPherson J, Jirjis JN, Roden DM.

Clin Pharmacol Ther. 2012 Jul;92(1):87-95. doi: 10.1038/clpt.2011.371. Epub 2012 May 16.

PMID:
22588608
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.

Price MJ, Tantry US, Gurbel PA.

Rev Cardiovasc Med. 2011;12(1):1-12. doi: 10.3909/ricm0590. Review.

PMID:
21546883
[PubMed - indexed for MEDLINE]
4.

Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?

Shahin MH, Johnson JA.

Curr Opin Cardiol. 2013 May;28(3):305-14. doi: 10.1097/HCO.0b013e32835f0bbc. Review.

PMID:
23478884
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Antiplatelet therapy: Does CYP2C19 genotype affect clinical outcome?

ten Berg JM, Deneer VH.

Nat Rev Cardiol. 2012 Mar 13;9(4):192-4. doi: 10.1038/nrcardio.2012.29. No abstract available.

PMID:
22411289
[PubMed - indexed for MEDLINE]
6.

Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.

Roberts JD, Wells GA, Le May MR, Labinaz M, Glover C, Froeschl M, Dick A, Marquis JF, O'Brien E, Goncalves S, Druce I, Stewart A, Gollob MH, So DY.

Lancet. 2012 May 5;379(9827):1705-11. doi: 10.1016/S0140-6736(12)60161-5. Epub 2012 Mar 29.

PMID:
22464343
[PubMed - indexed for MEDLINE]
7.

Pharmacogenetics of clopidogrel.

O'Connor SA, Hulot JS, Silvain J, Cayla G, Montalescot G, Collet JP.

Curr Pharm Des. 2012;18(33):5309-27. Review.

PMID:
22724417
[PubMed - indexed for MEDLINE]
8.

Pharmacogenomics of clopidogrel: evidence and perspectives.

Yin T, Miyata T.

Thromb Res. 2011 Oct;128(4):307-16. doi: 10.1016/j.thromres.2011.04.010. Epub 2011 May 18. Review.

PMID:
21592545
[PubMed - indexed for MEDLINE]
9.

Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program.

Shuldiner AR, Palmer K, Pakyz RE, Alestock TD, Maloney KA, O'Neill C, Bhatty S, Schub J, Overby CL, Horenstein RB, Pollin TI, Kelemen MD, Beitelshees AL, Robinson SW, Blitzer MG, McArdle PF, Brown L, Jeng LJ, Zhao RY, Ambulos N, Vesely MR.

Am J Med Genet C Semin Med Genet. 2014 Mar;166C(1):76-84. doi: 10.1002/ajmg.c.31396. Epub 2014 Mar 10.

PMID:
24616408
[PubMed - indexed for MEDLINE]
10.

Pharmacogenetics: Point-of-care genetic testing--a new frontier explored.

Barrett PM, Topol EJ.

Nat Rev Cardiol. 2012 May 1;9(6):315-6. doi: 10.1038/nrcardio.2012.63. No abstract available.

PMID:
22547169
[PubMed - indexed for MEDLINE]
11.

The pharmacogenetics of antiplatelet agents: towards personalized therapy?

Ahmad T, Voora D, Becker RC.

Nat Rev Cardiol. 2011 Aug 9;8(10):560-71. doi: 10.1038/nrcardio.2011.111. Review.

PMID:
21826075
[PubMed - indexed for MEDLINE]
12.

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.

Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Büttner HJ, Neumann FJ.

J Am Coll Cardiol. 2008 May 20;51(20):1925-34. doi: 10.1016/j.jacc.2007.12.056.

PMID:
18482659
[PubMed - indexed for MEDLINE]
Free Article
13.

Progress of antiplatelet pharmacogenomics.

Oestreich JH.

Curr Drug Targets. 2011 Nov;12(12):1848-58. Review.

PMID:
21718233
[PubMed - indexed for MEDLINE]
14.

[Genetic variability in the efficacy of clopidogrel].

Kristensen KE, Rasmussen HB, Hansen PR.

Ugeskr Laeger. 2013 Mar 11;175(11):729-32. Review. Danish.

PMID:
23480885
[PubMed - indexed for MEDLINE]
15.

No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.

Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, Schulz S, Mayer K, Bernlochner I, Schömig A, Kastrati A.

Eur Heart J. 2011 Jul;32(13):1605-13. doi: 10.1093/eurheartj/ehr155. Epub 2011 Apr 28.

PMID:
21527445
[PubMed - indexed for MEDLINE]
Free Article
16.

Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents.

Gurbel PA, Tantry US.

Circulation. 2012 Mar 13;125(10):1276-87; discussion 1287. doi: 10.1161/CIRCULATIONAHA.111.031195. No abstract available.

PMID:
22412089
[PubMed - indexed for MEDLINE]
Free Article
17.

Genetic variability in response to clopidogrel therapy and its clinical implications.

Yukhanyan L, Freynhofer MK, Siller-Matula J, Schrör K, Huber K.

Thromb Haemost. 2011 May;105 Suppl 1:S55-9. doi: 10.1160/THS10-11-0747. Epub 2011 Apr 11. Review.

PMID:
21479337
[PubMed - indexed for MEDLINE]
18.

Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents.

Oh IY, Park KW, Kang SH, Park JJ, Na SH, Kang HJ, Koo BK, Jeong YH, Hwang JY, Kwak CH, Park Y, Hwang SJ, Ko YG, Shin DJ, Jang Y, Kim HS.

Heart. 2012 Jan;98(2):139-44. doi: 10.1136/hrt.2011.227272. Epub 2011 Jun 23.

PMID:
21700758
[PubMed - indexed for MEDLINE]
19.

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Valente S, Antoniucci D, Abbate R, Gensini GF.

Pharmacogenet Genomics. 2007 Dec;17(12):1057-64.

PMID:
18004210
[PubMed - indexed for MEDLINE]
20.

CYP2C19 genotype-guided antiplatelet therapy in a patient with clopidogrel resistance.

Rai M, Seip RL, Gupta A, McKay RG, Hirst J, Thompson PD, Ruaño G.

Conn Med. 2012 May;76(5):267-72.

PMID:
22685981
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk